Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MBOT 
Microbot Medical Inc (MBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: MBOT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.88% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.36M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 1.25 | 52 Weeks Range 0.89 - 4.67 | Updated Date 10/19/2025 |
52 Weeks Range 0.89 - 4.67 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.52% | Return on Equity (TTM) -69.8% |
Valuation
Trailing PE - | Forward PE 31.75 | Enterprise Value 134834395 | Price to Sales(TTM) - |
Enterprise Value 134834395 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.89 | Shares Outstanding 67158044 | Shares Floating 45545939 |
Shares Outstanding 67158044 | Shares Floating 45545939 | ||
Percent Insiders 0.01 | Percent Institutions 8.88 |
Upturn AI SWOT
Microbot Medical Inc
Company Overview
History and Background
Microbot Medical Inc. was founded to develop and commercialize micro-robotic medical technologies aimed at transforming the way medical professionals treat patients. The company focuses on creating self-cleaning shunt technology and micro-robotic devices designed to navigate and treat areas difficult to access with traditional methods.
Core Business Areas
- Micro-Robotic Systems: Development and commercialization of micro-robotic devices for endoluminal surgery.
- Self-Cleaning Shunt Technology: Developing shunts with self-cleaning mechanisms to reduce the need for revisions and improve patient outcomes.
Leadership and Structure
The company has a management team consisting of a CEO, CFO, and other executives responsible for various aspects of the business, from research and development to commercialization and investor relations. The board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- Liberty Robotic System: A single-use, disposable robotic system designed for endovascular procedures. It aims to improve precision and reduce radiation exposure for physicians. Market share is currently small, as the product is not yet FDA approved and fully commercialized. Competitors include larger companies in the robotic surgery space, such as Intuitive Surgical (ISRG) and Stryker (SYK), that have established robotic systems.
- Self-Cleaning Shunt (SCS): A shunt designed with a micro-robotic mechanism to prevent blockages and reduce the need for revisions. This product is also not yet fully commercialized, and its market share is pending FDA approval. Competitors for shunt technologies include Medtronic (MDT) and Integra LifeSciences (IART).
Market Dynamics
Industry Overview
The medical robotics industry is experiencing rapid growth, driven by increasing demand for minimally invasive procedures, advancements in robotics technology, and an aging population. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Microbot Medical Inc. is positioning itself as a leader in the micro-robotics space, focusing on developing innovative solutions for niche medical applications. Its competitive advantage lies in its proprietary technology and expertise in micro-robotics.
Total Addressable Market (TAM)
The TAM for micro-robotic surgery and self-cleaning shunts is estimated to be several billion dollars. Microbot Medical Inc. aims to capture a significant portion of this market by offering unique and effective solutions.
Upturn SWOT Analysis
Strengths
- Proprietary micro-robotic technology
- Focus on unmet clinical needs
- Experienced management team
- Potential for high growth
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Limited commercialization experience
- Small market capitalization
Opportunities
- Growing demand for minimally invasive procedures
- Potential for partnerships with larger medical device companies
- Expansion into new therapeutic areas
- Technological advancements in robotics
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- ISRG
- MDT
- BSX
- SYK
Competitive Landscape
Microbot Medical Inc. competes with larger, more established medical device companies. Its competitive advantage lies in its proprietary technology and focus on niche markets. Its disadvantages include limited financial resources and commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage. Growth has primarily been reflected in the expansion of its intellectual property portfolio and progress towards regulatory approvals.
Future Projections: Future growth is highly dependent on obtaining regulatory approvals for its key products and successfully commercializing them. Analyst estimates vary widely, reflecting the inherent uncertainty in the company's development pipeline.
Recent Initiatives: Recent initiatives include advancing the development of the Liberty Robotic System and Self-Cleaning Shunt, securing patents, and pursuing regulatory approvals.
Summary
Microbot Medical is a high-risk, high-reward development-stage company. Its strengths lie in its innovative technology and potential to disrupt niche markets. However, it faces significant challenges, including regulatory hurdles, competition from established players, and limited financial resources. Success hinges on obtaining regulatory approvals and successfully commercializing its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Microbot Medical Inc
Exchange NASDAQ | Headquaters Hingham, MA, United States | ||
IPO Launch date 1992-03-25 | Co-Founder, President, CEO & Chairman Mr. Harel Gadot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 20 | Website https://microbotmedical.com |
Full time employees 20 | Website https://microbotmedical.com | ||
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.